Cargando…

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study

Objective: Our study aims to assess the effectiveness and safety profile of Disitamab Vedotin (DV, RC48-ADC), an innovative humanized anti-HER2 antibody conjugated with tubulin-disrupting antimitotic drug monomethyl auristatin E (MMAE) via a cleavable peptide linker. This treatment combined immune c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Yongbao, Zhang, Ruochen, Yu, Chenbo, Hong, Zhiwei, Lin, Le, Li, Tao, Chen, Jianhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461006/ https://www.ncbi.nlm.nih.gov/pubmed/37645442 http://dx.doi.org/10.3389/fphar.2023.1230395

Ejemplares similares

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
por: Huang, Haijun, et al.
Publicado: (2023)

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
por: Shi, Fan, et al.
Publicado: (2022)

Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer
por: Dai, Li, et al.
Publicado: (2022)

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review
por: Qi, Xiangjun, et al.
Publicado: (2022)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
por: Hoffman-Censits, Jean, et al.
Publicado: (2022)

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort
por: Zschäbitz, Stefanie, et al.
Publicado: (2023)

Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report
por: Qu, Fei, et al.
Publicado: (2023)

Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
por: Zheng, Yue, et al.
Publicado: (2023)

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
por: Takahashi, Shunji, et al.
Publicado: (2019)

Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma
por: Mimura, Yuji, et al.
Publicado: (2022)

Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review
por: van Hattum, Jons W., et al.
Publicado: (2021)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report
por: Wu, Qifeng, et al.
Publicado: (2022)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
por: Sun, Fengze, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor–Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
por: Wang, Li, et al.
Publicado: (2021)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021)

ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts
por: Li, Zhiwei, et al.
Publicado: (2023)

Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data
por: Lei, Yanna, et al.
Publicado: (2022)

Porcine Bladder Urothelial, Myofibroblast, and Detrusor Muscle Cells: Characterization and ATP Release
por: Cheng, Ying, et al.
Publicado: (2011)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
por: Xu, Chao, et al.
Publicado: (2023)

Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report
por: Fan, Shanmin, et al.
Publicado: (2023)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
por: Zhang, Lilong, et al.
Publicado: (2022)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
por: Shafique, Muhammad Ashir, et al.
Publicado: (2023)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

Effect of Enfortumab Vedotin Dose Adjustment on Efficacy in Metastatic Urothelial Carcinoma: A Retrospective Single-Center Experience 
por: Clennon, Anna, et al.
Publicado: (2023)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
por: Wei, Yongbao, et al.
Publicado: (2023)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
por: Giza, Agnieszka, et al.
Publicado: (2023)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
por: Vulsteke, Christof, et al.
Publicado: (2023)

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis
por: Qu, Hong-Chen, et al.
Publicado: (2020)

The Relationship of Pyroptosis-Related Genes, Patient Outcomes, and Tumor-Infiltrating Cells in Bladder Urothelial Carcinoma (BLCA)
por: Xie, Ruiyan, et al.
Publicado: (2022)

The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis
por: Sarfaty, Michal, et al.
Publicado: (2021)

Role of GATA3 in Early-Stage Urothelial Bladder Carcinoma Local Recurrence
por: Popov, Hristo, et al.
Publicado: (2023)

Overexpression of miRNA-93-5p Promotes Proliferation and Migration of Bladder Urothelial Carcinoma via Inhibition of KLF9
por: Li, Tao, et al.
Publicado: (2022)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
por: Huang, Kaituo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eqrj4gq4s8uv21tmdnpj149ipm